Sign In
Buy ANVS
$1.77
+0.0200 (+1.14%)
At Close: Jun 22, 2026
Berwyn, Pennsylvania--(Newsfile Corp. - July 2, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD
This Biotech Stock Is Up 884% In 2021, But It Could Go Even Higher
07:32am, Thursday, 10'th Jun 2021
With updates from clinical trials expected as soon as this month, anything is possible.
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
Annovis CEO on its Alzheimer's drug: ‘We may have something that gives hope to people'
08:24pm, Saturday, 29'th May 2021
Maria Maccecchini, Annovis CEO, joins Yahoo Finance's Alexis Christoforous and Kristin Myers to discuss the company's positive Alzheimer's drug study.
Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better
12:52pm, Monday, 24'th May 2021
Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic
ANVS Stock: 10% Decrease Pre-Market Explanation
06:23am, Monday, 24'th May 2021
The stock price of Annovis Bio Inc (NYSEAMERICAN: ANVS) decreased by 10% pre-market. This is why it happened.
5 Stocks To Watch For May 24, 2021
04:25am, Monday, 24'th May 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Nordson Corporation (NASDAQ: NDSN) to report quarterly earnings at $1.64 per share on revenue of $547.98 million after th
Annovis Bio, Inc. Announces Pricing of Public Offering
05:43pm, Sunday, 23'rd May 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD)
Annovis Bio: Positive Phase 2 Alzheimer's Cognition Data Strengthens Bullish Thesis
11:33am, Sunday, 23'rd May 2021
On May 21, ANVS doubled on phase 2 data for improved cognition in Alzheimer's disease. The stock has increased more than 600% since my first coverage this January.
3 Biotech Stocks That Jumped Higher Last Week
06:43am, Sunday, 23'rd May 2021
Find out what pushed them up to see if the good times can keep rolling.
Annovis Bio, Inc. Announces Proposed Public Offering of Common Stock
05:15pm, Friday, 21'st May 2021
Berwyn, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD
Annovis Bio (ANVS) Stock: Over 270% Increase Explanation
01:28pm, Friday, 21'st May 2021
The stock price of Annovis Bio Inc (NYSEAMERICAN: ANVS) increased by over 270% during intraday trading today. This is why it happened.
ANVS Stock: The Huge News Sending Annovis Bio Rocketing 200% Today
01:12pm, Friday, 21'st May 2021
A dual Alzheimer's-Parkinson's clinical trial is showing highly optimistic results for Annovis, and ANVS stock is up huge because of it. The post ANVS Stock: The Huge News Sending Annovis Bio Rocketin
Why Is Annovis Bio's Stock Surging Higher Today?
11:30am, Friday, 21'st May 2021
Annovis Bio Inc (NYSE:ANVS) shares are trading higher by 180% at $74 Friday morning after the company announced results from its double-blind placebo-controlled study of ANVS401, showing statistica
Annovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive Improvement
09:07am, Friday, 21'st May 2021
Annovis Bio Inc (NYSE: ANVS) has announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD), Parkinson's disease (PD). The data comes from
